Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Казанская государственная медицинская академия – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Казань, Россия; 2 ООО «Институт здоровья и долголетия “Разумед”», Казань, Россия; 3 ГАУЗ «Городская клиническая больница №7», Казань, Россия madina13@list.ru
Список исп. литературыСкрыть список 1. Mosca L, Hammond G, Mochari-Greenberger H et al. American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on High Blood. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013; 127 (11): 1254–63, e1-29. DOI: 10.1161/ CIR.0b013e318287cf2f 2. Чазова И.Е., Сметник В.П., Балан В.Е. и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе: консенсус российских кардиологов и гинекологов. Системные гипертензии. 2008; (3): 26–39. Chazova IE, Smetnik VP, Balan VE et al. Management of women with cardiovascular risk in peri- and postmenopausal women: consensus of Russian cardiologists and gynecologists. Systemic hypertension. 2008; (3): 26–39 (in Russian). 3. Погосова Н.В., Оганов Р.Г., Бойцов С.А. и др. Мониторинг вторичной профилактики ишемической болезни сердца в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология. 2015; 55 (12): 99–107. Pogosova NV, Oganov RG, Boitsov SA et al. Monitoring of secondary prevention of coronary heart disease in Russia and Europe: results of the Russian part of the international multicenter EUROASPIRE IV study. Cardiology. 2015; 55 (12): 99–107 (in Russian). 4. Benjamin EJ, Muntner P, Alonso A et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2019 update: a report from the American Heart Association. Circulation. 2019; 139: e56–e528. DOI: 10.1161/CIR. 0000000000000659 5. Сердечно-сосудистые заболевания. ВОЗ. URL: https://www.who. int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Cardiovascular diseases. World Health Organization. URL: https:// www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (in Russian). 6. Пан Ги Мун. Послание по случаю Международного дня пожилых людей. URL: http://www.un.org/ ru/sg/messages/2013/olderpersonsday.shtml Pan Gi Mun. Message on the occasion of the International Day of the Elderly. URL: http://www.un.org/ ru/sg/messages/2013/olderpersonsday.shtml (in Russian). 7. El Khoudary SR. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: a narrative review. Maturitas. 2017; 104: 44–53. DOI: 10.1016/j.maturitas.2017.08.003 8. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29: 767. 9. Lobo RA, Davis SR, de Villiers TJ et al. Prevention of diseases after menopause. Climacteric. 2014; 17: 540–56. DOI: 10.3109/13697137. 2014.933411 10. Hodis HN, Neves-e-Castro M. Menopausal hormone therapy and prevention of chronic diseases: IMS members react to the recent JAMA paper. Climacteric. 2014; 17 (1): 99–101. PMID: 24571029. 11. Menopause: diagnosis and management. NICE guideline [NG23]. Last updated: 05 December 2019. 12. Chester RC, Kling JM, Manson JE. What the Women's Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018; 41 (2): 247–52. DOI: 10.1002/clc.22891 13. Naftolin F, Friedenthal J, Nachtigall R, Nachtigall L. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment. F1000Res. 2019; 8: F1000 Faculty Rev-1576. DOI: 10.12688/f1000research.15548.1 14. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24 (7): 728–53. DOI: 10.1097/GME.0000000000000921 15. Miller VM, Black DM, Brinton EA et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009; 2 (3): 228–39. DOI: 10.1007/s12265-009-9104-y 16. Mehta JM, Chester RC, Kling JM. The timing hypothesis: hormone therapy for treating symptomatic women during menopause and its relationship to cardiovascular disease. J Womens Health. 2019; 28 (5): 705–11. DOI: 10.1089/jwh.2018.7201 17. Moreau KL, Hildreth KL, Meditz AL et al. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012; 97 (12): 4692–700. DOI: 10.1210/jc.2012-2244 18. Boardman HM, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopasual women. Cochrane Database Syst Rev. 2015. 19. Alonzo MD, Bounous VE, Villa M, Biglia N. Current evidence of the oncological benefit-risk profile of hormone replacement therapy. Medicina. 2019; 55: 573. DOI: 10.3390/medicina55090573 20. De Smedt D, De Bacquer D, De Sutter J et al. The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol. 2016; 209: 284–90. 21. Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart Fail. 2016; 4: 78–87. DOI: 10.1016/j.jchf. 2015.08.006 22. Гиперлипопротеидемия(а) как опасное генетически обусловленное нарушение липидного обмена и фактор риска атеротромбоза и сердечно-сосудистых заболеваний. Российский кардиологический журнал. 2019; 24 (5): 101–8. DOI: 10.15829/1560-4071- 2019-5-101-108 Hyperlipoproteidemia (a) as a dangerous genetically determined violation of lipid metabolism and a risk factor for atherothrombosis and cardiovascular diseases. Russ J Cardiol. 2019; 24 (5): 101–8. DOI: 10.15829/1560-4071- 2019-5-101-108 (in Russian). 23. Hanggi W, Lippuner K, Riesen W et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol. 1997; 104: 708–17. 24. Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001; 76 (1): 13–24. DOI: 10.1016/S0015-0282(01)01829-5 25. Kessler EL, Rivaud MR, Vos MA, Van Veen TA. Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease. Biol Sex Differ. 2019; 10 (7). 26. Miller RJH, Mikami Y, Heydari B et al. Sex-specific relationships between patterns of ventricular remodelling and clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020; 21: 983–990. 27. Sarri G, Pedder H, Dias S et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG. 2017; 124: 1514. 28. Hodis HN, Mack WJ, Henderson VW. Effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016; 374: 1221–31. DOI: 10.1056/ NEJMoa1505241 29. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394 (10204): 1159–68. DOI: 10.1016/S0140-6736(19)31709-X 30. Hodis HN, Mack WJ, Henderson VW. Effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016; 374: 1221–31. DOI: 10.1056/ NEJMoa1505241 31. Santen RJ. Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. Menopause. 2017; 24: 589–95. DOI: 10.1097/GME.0000000000000847 32. Dinger J, Bardenheuer K, Heinemann К. Drospirenone plus estradiol and the risk of setious cardiovascular events in postmenopausal women. Climacteric. 2016; 19 (4): 349–56. DOI: 10.1080/13697137. 2016.1183624 33. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases [published correction appears in BMJ. 2019 Jan 15;364:l162]. BMJ. 2019;364:k4810. Published 2019 Jan 9. doi:10.1136/bmj.k4810 34. Росстат. Численность населения Российской Федерации по полу и возрасту на 1 января 2022 г. М., 2022. URL: https:// rosstat.gov.ru/ compendium/document/13284 (accessed: 05.10.2022). Rosstat. The population of the Russian Federation by gender and age as of 01.01.2022. Moscow, 2022. URL: ttps://rosstat.gov.ru/compendium/document/13284 (accessed: 05.10.2022) (in Russian) 35. Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. КР117. М., 2021. Menopause and menopause in women. Clinical Recommendations of the ROAG. CR 117. Moscow, 2021 (in Russian). 36. Our World in Data - Why do women live longer than men? Available at: https://ourworldindata.org/why-do-women-live-longer-than-men; Accessed: от 09.01.2022. 37. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev 2008;60:210-241. 38. Menazza S, Murphy E. The expanding complexity of estrogen receptor signaling in the cardiovascular system. Circ Res. 2016; 118: 994–1007. 39. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006; 27: 575–605. 40. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 2015; 294: 63–69. 41. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016; 16: 626–38.